TGFB1 and neoplasm: However, BBR treatment significantly suppressed SMAD 2/3 phosphorylation in ECs but not in the background tumor cells (Figure 6E,F and Supplementary Figure S6), indicating that BBR inhibited TGF-β1 signaling in vivo.